Nelson P. Barrera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nelson P. Barrera has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
José Cordero
Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile
2 shared publicationsPedro H. Silva
Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile
2 shared publicationsAlexis M. Kalergis
Millennium Institute on Immunology and Immunotherapy, Santiago, 8330025, Chile
1 shared publicationBenjamin Lozano
Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile
1 shared publicationCristian Vargas
MELISA Institute, Concepción 4130000, Chile
1 shared publicationDaniela Villalobos
Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile
1 shared publication
Latest Publications
- Open Access
Tocilizumab induces significant changes in longitudinal proteomes of blood serum from patients with severe COVID-19 pneumonia
Coronavirus disease 2019 (COVID-19) shows highly variable clinical outcomes that are not fully explained by age or comorbidities, underscoring the importance of host molecular responses in determining disease severity. Proteomic and multi-omics studies have linked severe COVID-19 to profound dysregulation of immune, inflammatory, and coagulation pathways, and have shown that circulating protein signatures can predict clinical trajectories. Tocilizumab (TCZ), a monoclonal antibody targeting the interleukin-6 receptor (IL-6R), is an established therapy for IL-6–driven inflammatory diseases and can normalize aberrant molecular profiles. Here, we applied longitudinal serum proteomics to patients with severe SARS-CoV-2 pneumonia treated with TCZ to further characterize how IL-6R blockade reshapes the systemic inflammatory milieu. After TCZ administration, several clinical and inflammatory markers, including C-reactive protein (CRP), CCL5 and CXCL10, decreased. Proteomic profiling revealed that TCZ exerts a sustained effect on the serum proteome, with the most pronounced changes emerging 7 days after treatment. These changes were associated with a broad reconfiguration of the proteomic profile toward a pattern resembling a healthy physiological state, characterized by the restoration of key protein abundances to levels comparable to those observed under homeostatic conditions. Collectively, our findings support that TCZ treatment contributes to the normalization of the inflammatory state in severe COVID-19 and represents a viable therapeutic option for managing the acute inflammatory phase of the disease, while also highlighting additional pathways and biomarkers involved in this recovery process.
Open AccessTocilizumab induces significant changes in longitudinal proteomes of blood serum from patients with severe COVID-19 pneumonia
Coronavirus disease 2019 (COVID-19) shows highly variable clinical outcomes that are not fully explained by age or comorbidities, underscoring the importance of host molecular responses in determining disease severity. Proteomic and multi-omics studies have linked severe COVID-19 to profound dysregulation of immune, inflammatory, and coagulation pathways, and have shown that circulating protein signatures can predict clinical trajectories. Tocilizumab (TCZ), a monoclonal antibody targeting the interleukin-6 receptor (IL-6R), is an established therapy for IL-6–driven inflammatory diseases and can normalize aberrant molecular profiles. Here, we applied longitudinal serum proteomics to patients with severe SARS-CoV-2 pneumonia treated with TCZ to further characterize how IL-6R blockade reshapes the systemic inflammatory milieu. After TCZ administration, several clinical and inflammatory markers, including C-reactive protein (CRP), CCL5 and CXCL10, decreased. Proteomic profiling revealed that TCZ exerts a sustained effect on the serum proteome, with the most pronounced changes emerging 7 days after treatment. These changes were associated with a broad reconfiguration of the proteomic profile toward a pattern resembling a healthy physiological state, characterized by the restoration of key protein abundances to levels comparable to those observed under homeostatic conditions. Collectively, our findings support that TCZ treatment contributes to the normalization of the inflammatory state in severe COVID-19 and represents a viable therapeutic option for managing the acute inflammatory phase of the disease, while also highlighting additional pathways and biomarkers involved in this recovery process.
- Open Access
- 3 September 2024
- Published by MDPI AG in Preprints.org
Acetylcholine Activates a Regenerative Vasodilator Mechanism That Is Sensitive to Nitric Oxide Production
Conduction of vasodilator signals plays an important role in the coordination of blood flow distribution. It is thought that endothelium-dependent vasodilation’s are conducted by electrotonic spread through gap junctions of the endothelial cell hyperpolarization generated at the stimulation site. However, nitric oxide (NO) was found to reduce the propagation of vasodilator responses, suggesting the participation of this signaling molecule in the mechanism of conduction. Mouse cremasteric arterioles were stimulated through micro-application of ACh or the NO donor, S-nitroso-N-acetylpenicillamine (SNAP) and the responses were evaluated at the stimulation site (local) and at sites located 500, 1000 and 2000 µm upstream from the vessel segment stimulated with ACh. The response to ACh spread along the entire vessel showing a slight decay and, in contrast, the dilation evoked by SNAP was restricted to the stimulation site, independently of the magnitude of the response. Blockade of NO production with 100 µM NG-nitro-L-arginine methyl ester (L-NAME) or 100 µM NG-nitro-L-arginine (L-NA) reduced the resting diameter by 10-12% (n=4), but the combination of two NO blockers enhanced the basal vasoconstrictor tone by ~38% (n=5) and inhibited the local (~45%) and conducted (~20-35%) responses to ACh. Interestingly, the conduction of ACh-induced vasodilation increased along the vessel length in the presence of L-NAME and L-NA. In addition, endothelial cell hyperpolarization blockade exclusively at the stimulation site through microsuperfusion of tetraethylammonium inhibited the local vasodilation, but not the conduction of the response. These results indicate that ACh activates a NO-sensitive regenerative vasodilator mechanism that is coupled to the activation of NO production and endothelium-dependent hyperpolarization along the vessel length.
- 3 September 2024
- Published by MDPI AG in Preprints.org
Open AccessAcetylcholine Activates a Regenerative Vasodilator Mechanism That Is Sensitive to Nitric Oxide Production
Conduction of vasodilator signals plays an important role in the coordination of blood flow distribution. It is thought that endothelium-dependent vasodilation’s are conducted by electrotonic spread through gap junctions of the endothelial cell hyperpolarization generated at the stimulation site. However, nitric oxide (NO) was found to reduce the propagation of vasodilator responses, suggesting the participation of this signaling molecule in the mechanism of conduction. Mouse cremasteric arterioles were stimulated through micro-application of ACh or the NO donor, S-nitroso-N-acetylpenicillamine (SNAP) and the responses were evaluated at the stimulation site (local) and at sites located 500, 1000 and 2000 µm upstream from the vessel segment stimulated with ACh. The response to ACh spread along the entire vessel showing a slight decay and, in contrast, the dilation evoked by SNAP was restricted to the stimulation site, independently of the magnitude of the response. Blockade of NO production with 100 µM NG-nitro-L-arginine methyl ester (L-NAME) or 100 µM NG-nitro-L-arginine (L-NA) reduced the resting diameter by 10-12% (n=4), but the combination of two NO blockers enhanced the basal vasoconstrictor tone by ~38% (n=5) and inhibited the local (~45%) and conducted (~20-35%) responses to ACh. Interestingly, the conduction of ACh-induced vasodilation increased along the vessel length in the presence of L-NAME and L-NA. In addition, endothelial cell hyperpolarization blockade exclusively at the stimulation site through microsuperfusion of tetraethylammonium inhibited the local vasodilation, but not the conduction of the response. These results indicate that ACh activates a NO-sensitive regenerative vasodilator mechanism that is coupled to the activation of NO production and endothelium-dependent hyperpolarization along the vessel length.